{"brief_title": "An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD", "brief_summary": "The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.", "condition": "Maculopathy, Age-Related", "intervention_type": "Drug", "intervention_name": "anecortave acetate", "criteria": "Patients at least 50 years of age, of any race, and either sex with a clinical diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye.", "gender": "All", "minimum_age": "50 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00058994.xml"}